Vascular Lesions Clinical Trial
— MISAGO ILIACOfficial title:
Physician Initiated Multi-center Belgian-German Trial Investigating the Terumo Misago Stent in the Treatment of TASC A & B Iliac Lesions
Verified date | August 2014 |
Source | Flanders Medical Research Program |
Contact | n/a |
Is FDA regulated | No |
Health authority | Belgium: Institutional Review Board |
Study type | Observational |
The objective of this clinical study is to evaluate, in a controlled setting, the long-term (up to 24 months) outcome of the self-expanding nitinol rapid-exchange Misago (Terumo) stent in TASC A and B iliac lesions.
Status | Completed |
Enrollment | 100 |
Est. completion date | October 2013 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator) - Patient presenting a score from 2 to 5 following Rutherford classification - Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study - Patient is >18 years old - Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study - Patient is eligible for treatment with the Misago (Terumo) - The target lesion is either a modified TASC-II class A or B lesion with one of the listed specifications: - Type A lesions - Unilateral or bilateral stenoses of the Common Iliac Artery - Unilateral or bilateral single short (=3 cm) stenosis of the External Iliac Artery - Type B lesions - Unilateral Common Iliac Artery occlusion - Single or multiple stenosis totaling 3-10 cm involving the External Iliac Artery not extending into the Common Femoral Artery - Unilateral External Iliac Artery occlusion not involving the origins of Internal Iliac Artery or Common Iliac Artery - The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation - There is angiographic evidence of a patent Common an Deep Femoral Artery Exclusion Criteria: - The target lesion is either a modified TASC-II class B lesion with aortic lesion involvement: - Short (=3 cm) stenosis of infrarenal aorta - The target lesion is either a modified TASC-II class C or D lesion with aortic lesion involvement: - Presence of aneurysm at the level of the iliac arteries - Previously implanted stent(s) at the same lesion site - Reference segment diameter is not suitable for available stent design - Untreatable lesion located at the distal outflow arteries - Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure - Patients refusing treatment - Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated - Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site - Perforation at the angioplasty site evidenced by extravasation of contrast medium - Patients with a history of prior life-threatening contrast medium reaction - Patients with known hypersensitivity to nickel-titanium - Patients with uncorrected bleeding disorders - Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding - Life expectancy of less than twelve months - Any planned surgical intervention/procedure within 30 days of the study procedure - Any patient considered to be hemodynamically unstable at onset of procedure - Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Belgium | Imelda Hospital | Bonheiden | Antwerp |
Belgium | AZ Sint-Blasius | Dendermonde | East-Flanders |
Belgium | UZ Gent | Gent | East-Flanders |
Germany | Herzzentrum Leipzig | Leipzig | Sachsen |
Germany | St Franziskus Hospital | Münster | Nordrhein-Westfalen |
Lead Sponsor | Collaborator |
---|---|
Flanders Medical Research Program |
Belgium, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary patency, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without Target Lesion Revascularization (TLR) within 12 months. | 12 months | No | |
Secondary | Technical success, defined as the ability to achieve final residual angiographic stenosis no greater than 30%. | procedural | No | |
Secondary | Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without prior TLR are defined as being primary patent at the given follow-up. | 1 & 24 months | No | |
Secondary | Clinical success, defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure Rutherford classification | 1, 12 & 24 months | No | |
Secondary | Serious adverse events | up to 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01861860 -
OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA
|
N/A | |
Terminated |
NCT01305174 -
Iliac, Common and External (ICE) Artery Stent Trial
|
Phase 4 | |
Recruiting |
NCT02468453 -
VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation
|
N/A |